home > news > detailed info

INTEGRA Biosciences’ VOYAGER pipettes help to guide the treatment of chronic pain

INTEGRA Biosciences

El Paso Pain Center, Texas, US, is using the VOYAGER adjustable tip spacing pipette from INTEGRA Biosciences to streamline its pharmacogenomics (PGx) testing of saliva samples. These results are used to identify genetic variations that are known to affect the metabolism of certain medications, causing them to become ineffective in managing pain, or to have unwelcome side effects.

El Paso Pain Center carries out approximately 45 PGx tests each week on patient samples from its multiple clinics across the states of Texas and New Mexico. Maria Esquivel, Clinical Laboratory Manager at El Paso Pain Center, explained: “Our main goal is to maintain quick turnaround times for our patients, so that they can receive the answers and care they need as soon as possible. We perform DNA extraction in 96 well plates, but carry out analysis using 384 well plates. The VOYAGER pipette’s automatic tip spacing adjustment makes it very convenient for us to rapidly transfer samples between these different labware formats, speeding up this repetitive task and improving our turnaround times. It has also demonstrated high precision – which reassures us that our results are accurate and reliable – and enables tasks to be performed one handed, reducing the likelihood of pipetting errors and repetitive strain injuries.”

“We are very satisfied with the VOYAGER, and we’re looking forward to continuing our relationship with INTEGRA in the future. We plan to open several new clinics to reach more patients, so we’ll need to take on more pipetting platforms to cope with the increasing demand and sustain our rapid turnaround times,” Maria concluded.

For more information about INTEGRA Biosciences, visit
phone 01635 797000
email 2 Rivermead Business Park Thatcham Berkshire, RG19 4EP
Print this page
Send to a friend
News and Press Releases

Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD) for filing. The FDA has set October 26, 2023, as the Prescription Drug User Fee Act (PDUFA) target action date.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement